

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0071
Drug name and formulations:		Flunarizine
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Potential for weight gain, extrapyramidal symptoms. Few interactions noted
Clinical effectiveness	<i>Established licensed product</i>	Unlicensed in the UK. Two small-scale studies indicating non-inferiority to other prophylactic agents.
Strength of evidence		Small scale evidence not deemed robust. Comparable to other preventative treatments for migraine e.g. tricyclic antidepressants based on historical data
Cost effectiveness or resource impact	£	Cost per dose is £2.40 per dose at £1,300 for single year treatment before it gets into primary care. Unpredictable in primary care.
Place of therapy relative to available treatments	<i>1/2nd tier</i>	3 rd or 4 th line agent. Patient to have tried or found to be intolerant to first-line preventative agents.
National guidance and priorities	<i>NICE, MTRAC</i>	NICE Evidence summary
Local health priorities	<i>CCG views</i>	CCGs supportive if restricted to specialist use only.
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	Specialist use only.

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	N/A
Not approved and rationale:	N/A
Formulary status (RAG) and rationale	RED status. <u>Rationale</u> : Specialist input required. Small patient numbers anticipated.
Implementation requirements:	N/A
Implementation monitoring:	N/A